

Comments on NICE Appraisal Consultation Document for the Single Technology Appraisal on cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]

**British Association of Dermatologists
Therapy & Guidelines sub-committee**

On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Appraisal Consultation Document.

We understand that the combination therapy has not been approved because the QALY gained is not cost-effective for the NHS at the current price of the medication compared to single BRAF treatment. We wish to point out that, with combination treatment, there are significantly less number of SCCs and keratoacanthomas which have a cost implication as they require excision, usually under a dermatologist. The rate of SCC/KA development in single agent BRAF is about 20% reduced to around 9% with combination treatment.

Dr Pamela McHenry
Chair
Therapy & Guidelines sub-committee